ATE412639T1 - Biarylsubstituierte triazole als natriumkanalblocker - Google Patents

Biarylsubstituierte triazole als natriumkanalblocker

Info

Publication number
ATE412639T1
ATE412639T1 AT04720360T AT04720360T ATE412639T1 AT E412639 T1 ATE412639 T1 AT E412639T1 AT 04720360 T AT04720360 T AT 04720360T AT 04720360 T AT04720360 T AT 04720360T AT E412639 T1 ATE412639 T1 AT E412639T1
Authority
AT
Austria
Prior art keywords
biaryl
sodium channel
channel blockers
substituted triazoles
triazoles
Prior art date
Application number
AT04720360T
Other languages
English (en)
Inventor
Prasun Chakravarty
Michael Fisher
Brenda Palucki
Min Park
William Parsons
Bishan Zhou
James Carey
Douglas Frantz
Michael Kress
Damian Weaver
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE412639T1 publication Critical patent/ATE412639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04720360T 2003-03-18 2004-03-12 Biarylsubstituierte triazole als natriumkanalblocker ATE412639T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18

Publications (1)

Publication Number Publication Date
ATE412639T1 true ATE412639T1 (de) 2008-11-15

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720360T ATE412639T1 (de) 2003-03-18 2004-03-12 Biarylsubstituierte triazole als natriumkanalblocker

Country Status (34)

Country Link
US (2) US7326726B2 (de)
EP (1) EP1606269B1 (de)
JP (1) JP4482554B2 (de)
KR (1) KR100737721B1 (de)
CN (2) CN101289428A (de)
AR (1) AR044503A1 (de)
AT (1) ATE412639T1 (de)
AU (1) AU2004221885C1 (de)
BR (1) BRPI0408407A (de)
CA (1) CA2519252C (de)
CL (1) CL2004000551A1 (de)
CY (1) CY1108720T1 (de)
DE (1) DE602004017438D1 (de)
DK (1) DK1606269T3 (de)
EC (1) ECSP056018A (de)
EG (1) EG25994A (de)
ES (1) ES2314387T3 (de)
HR (1) HRP20050816A2 (de)
IS (1) IS8001A (de)
JO (1) JO2480B1 (de)
MA (1) MA27665A1 (de)
MX (1) MXPA05009847A (de)
MY (1) MY142651A (de)
NO (1) NO20054775L (de)
NZ (1) NZ542205A (de)
PE (1) PE20041066A1 (de)
PL (1) PL1606269T3 (de)
PT (1) PT1606269E (de)
RU (1) RU2356897C2 (de)
SI (1) SI1606269T1 (de)
TW (1) TWI337605B (de)
UA (1) UA81660C2 (de)
WO (2) WO2004083190A1 (de)
ZA (1) ZA200506906B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
EP1943216B1 (de) 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
NZ579403A (en) * 2007-02-08 2012-03-30 Synta Pharmaceuticals Corp Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
HUE034911T2 (hu) 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
EP2588197B1 (de) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Kondensierte heterozyklische verbindungen als ionenkanalmodulatoren
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (de) 2011-07-01 2018-04-28
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014152738A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
EP3691634A4 (de) 2017-10-05 2021-03-31 Biogen Inc. Verfahren zur herstellung von alpha-carboxamid-pyrolidin-derivaten
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
BR112020018403A2 (pt) * 2018-03-09 2020-12-22 Pi Industries Ltd. Compostos heterocíclicoscomo fungicidas
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (de) * 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
IL145508A0 (en) 1999-03-26 2002-06-30 Euro Celtique Sa Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
JP2004532234A (ja) * 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
US6875782B2 (en) * 2002-07-09 2005-04-05 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers

Also Published As

Publication number Publication date
JP2006520782A (ja) 2006-09-14
AU2004221885B2 (en) 2010-04-22
DE602004017438D1 (de) 2008-12-11
CL2004000551A1 (es) 2005-01-21
TWI337605B (en) 2011-02-21
US20050119261A1 (en) 2005-06-02
PE20041066A1 (es) 2005-01-22
NO20054775D0 (no) 2005-10-17
US7326726B2 (en) 2008-02-05
RU2005132168A (ru) 2006-04-27
NZ542205A (en) 2008-11-28
JP4482554B2 (ja) 2010-06-16
MY142651A (en) 2010-12-15
EP1606269B1 (de) 2008-10-29
DK1606269T3 (da) 2009-02-09
IS8001A (is) 2005-08-29
ZA200506906B (en) 2007-02-28
HRP20050816A2 (hr) 2006-04-30
CN101289428A (zh) 2008-10-22
PT1606269E (pt) 2008-12-16
CA2519252A1 (en) 2004-09-30
ES2314387T3 (es) 2009-03-16
KR100737721B1 (ko) 2007-07-11
RU2356897C2 (ru) 2009-05-27
US7572822B2 (en) 2009-08-11
NO20054775L (no) 2005-12-16
AU2004221885A1 (en) 2004-09-30
TW200505876A (en) 2005-02-16
SI1606269T1 (sl) 2009-02-28
ECSP056018A (es) 2006-01-27
EG25994A (en) 2012-11-28
EP1606269A1 (de) 2005-12-21
BRPI0408407A (pt) 2006-03-21
CA2519252C (en) 2008-11-18
AR044503A1 (es) 2005-09-14
WO2004083190A1 (en) 2004-09-30
PL1606269T3 (pl) 2009-04-30
JO2480B1 (en) 2009-01-20
CN1788002A (zh) 2006-06-14
CY1108720T1 (el) 2013-09-04
KR20050109583A (ko) 2005-11-21
MA27665A1 (fr) 2005-12-01
US20080171777A1 (en) 2008-07-17
UA81660C2 (ru) 2008-01-25
AU2004221885C1 (en) 2010-09-23
WO2004083189A1 (en) 2004-09-30
MXPA05009847A (es) 2005-12-05

Similar Documents

Publication Publication Date Title
DE602004017438D1 (de) Biarylsubstituierte triazole als natriumkanalblocker
DK1663235T3 (da) Beskyttede pyrazinoylguanidin-natriumkanal-blokkere
ATE294805T1 (de) Triazoloverbindungen als mmp-inhibitoren
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
IL176451A0 (en) Novel 2-heteroaryl-substituted benzimidazole derivative
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
EP1542686A4 (de) Aryl-substituierte hydantoin-verbindungen und ihre verwendung als natriumkanalblocker
NO2015005I2 (no) Flutemetamol (18F)
EP1619881A4 (de) Abbildungseinrichtung
NL1027084A1 (nl) Gesubstitueerde triazoolderivaten als oxytocine-antagonisten.
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE365161T1 (de) Pyrazolverbindungen
DE602004013559D1 (de) G-lactamderivate als prostaglandinagonisten
ATE364601T1 (de) Substituierte pyrazolverbindungen
EP1681700A4 (de) Unterbrecherschalter
ATE427945T1 (de) Imidazolderivate
ITTO20040454A1 (it) Struttura anteriore di motociclo
ATE342335T1 (de) Bleichmittelzusammensetzungen
DE502004012042D1 (de) Lichtleitanordnung
ATE360676T1 (de) Bleichmittel
IL175438A0 (en) 4-substituted imidazoles
ATE343625T1 (de) Bleichmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1606269

Country of ref document: EP

EEFA Change of the company name